TN2010000049A1 - Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same - Google Patents

Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Info

Publication number: TN2010000049A1
Authority: TN; Tunisia
Prior art keywords: methods; compositions; arylamino; inhibitors; mek
Prior art date: 2007-07-30

Application number

TNP2010000049A

Other languages

English (en)

Inventor

Jean Michel Vernier

Colin Edward Rowlings

Jean Luc Girardet

Stuart Dimock

Barry Quart

Jeffrey N Miner

Original Assignee

Ardea Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-30

Filing date

2010-01-29

Publication date

2011-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-30 Priority claimed from US11/830,733 external-priority patent/US8101799B2/en

2010-01-29 Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc

2011-09-26 Publication of TN2010000049A1 publication Critical patent/TN2010000049A1/fr

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
- A01N41/06—Sulfonic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Agronomy & Crop Science (AREA)
Plant Pathology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Pest Control & Pesticides (AREA)
Rheumatology (AREA)
Dentistry (AREA)

TNP2010000049A 2007-07-30 2010-01-29 Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same TN2010000049A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US11/830,733 US8101799B2 (en)	2005-07-21	2007-07-30	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P	2008-03-06	2008-03-06
US3446608P	2008-03-06	2008-03-06
US4488608P	2008-04-14	2008-04-14
PCT/US2008/071392 WO2009018233A1 (fr)	2007-07-30	2008-07-28	Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci

Publications (1)

Publication Number	Publication Date
TN2010000049A1 true TN2010000049A1 (en)	2011-09-26

Family

ID=40304796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2010000049A TN2010000049A1 (en)	2007-07-30	2010-01-29	Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Country Status (22)

Country	Link
EP (1)	EP2184984A4 (fr)
JP (3)	JP2010535232A (fr)
KR (3)	KR20100092424A (fr)
CN (2)	CN103479604B (fr)
AP (1)	AP2817A (fr)
AU (2)	AU2008282338B2 (fr)
BR (1)	BRPI0815659A2 (fr)
CA (1)	CA2693390C (fr)
CO (1)	CO6470808A2 (fr)
CR (1)	CR11244A (fr)
DO (1)	DOP2010000045A (fr)
EA (2)	EA032294B1 (fr)
EC (1)	ECSP109910A (fr)
HN (1)	HN2010000203A (fr)
IL (1)	IL203296A (fr)
MA (1)	MA31881B1 (fr)
MX (1)	MX2010001244A (fr)
NZ (1)	NZ582929A (fr)
PH (1)	PH12015501914A1 (fr)
SV (1)	SV2010003469A (fr)
TN (1)	TN2010000049A1 (fr)
WO (1)	WO2009018233A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EA201001639A1 (ru) *	2008-04-14	2011-06-30	Арди Байосайенсиз, Инк.	Композиции и способы их получения и применения
BR122021020475B1 (pt) *	2008-09-09	2022-06-07	F. Hoffmann-La Roche Ag	Polimorfos de acil sulfonamidas, seu uso, seu processo de preparação e composição farmacêutica que os compreende
JP5792621B2 (ja)	2008-09-26	2015-10-14	オンコメッドファーマシューティカルズインコーポレイテッド	ｆｒｉｚｚｌｅｄ結合剤およびその使用
CN103948600A (zh)	2009-03-11	2014-07-30	阿迪生物科学公司	用于治疗特定癌症的包含rdea119/bay869766的药物组合
UY32486A (es) *	2009-03-11	2010-10-29	Ardea Biosciences Inc	Tratamiento del cáncer de páncreas
BR112012008599A2 (pt)	2009-10-13	2019-09-24	Allostem Therapeutics Llc	composto da formula (i), composto da fórmula (ia), composto da fórmula (ic), composto da fórmula (ii), composto da fórmula (iia), composto, método para tratamento de um transtorno hiperproliferativo em um mamífero, que inclui um humano, método para tratamento de uma doença, condição ou transtorno inflamatório em um mamífero, que inclui um humano, método para tratamento de um transtorno ou condição que é modulada pela cascata de meik em um mamífero, que inclui um himano, método para tratar ou prevenir câncer, composição farmacêutica e método para inibir uma enzima mek
EP2491015A1 (fr) *	2009-10-21	2012-08-29	Bayer Pharma Aktiengesellschaft	Benzosulfonamides substitués
TWI535445B (zh)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) *	2011-02-23	2012-08-29	苏州波锐生物医药科技有限公司	氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
JP6363502B2 (ja) *	2011-04-28	2018-07-25	スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ	Ｈｓｐ９０併用療法
PH12013502446A1 (en) *	2011-05-27	2014-01-20	Bayer Ip Gmbh	Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
WO2013086260A2 (fr) *	2011-12-09	2013-06-13	Oncomed Pharmaceuticals, Inc.	Thérapie d'association pour le traitement du cancer
WO2013109142A1 (fr)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
CN104394855A (zh) *	2012-05-31	2015-03-04	拜耳医药股份有限公司	用于测定肝细胞癌(hcc)患者的治疗的有效响应的生物标记
KR20220093389A (ko) *	2012-06-04	2022-07-05	파마싸이클릭스 엘엘씨	브루톤 타이로신 키나아제 저해제의 결정 형태
SI3702351T1 (sl) *	2012-10-19	2024-03-29	Array Biopharma Inc.,	Formulacija, ki obsega inhibitor mek
EP2916859B1 (fr)	2012-11-02	2017-06-28	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Méthode de réduction des effets secondaires chez un patient souffrant de cancer traité par un inhibiteur de la mek
CN105073195A (zh)	2013-02-04	2015-11-18	昂科梅德制药有限公司	使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
EP2848246A1 (fr)	2013-09-13	2015-03-18	Bayer Pharma Aktiengesellschaft	Compositions pharmaceutiques contenant du refametinib
WO2015041534A1 (fr)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk en combinaison avec raf/erk/mek
US9629851B2 (en)	2013-09-20	2017-04-25	Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis	ROCK in combination with MAPK pathway
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (fr)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions pour le traitement du cancer
WO2015196072A2 (fr)	2014-06-19	2015-12-23	Whitehead Institute For Biomedical Research	Utilisations d'inhibiteurs de kinase pour l'induction et le maintien de la pluripotence
CN106535931A (zh) *	2014-08-25	2017-03-22	艾慕恩治疗公司	卵蛋白制剂及其制备方法
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
TW201904577A (zh)	2017-06-16	2019-02-01	美商貝達醫藥公司	N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
BR112021018168B1 (pt)	2019-03-21	2023-11-28	Onxeo	Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
WO2021067772A1 (fr) *	2019-10-04	2021-04-08	Sumitomo Dainippon Pharma Oncology, Inc.	Formulations d'inhibiteur d'axl
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
US12371667B2 (en)	2021-05-13	2025-07-29	Washington University	Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (fr)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Méthodes de pronostic et de traitement de patients souffrant de mélanome
CN118834328B (zh) *	2024-07-02	2025-09-16	江苏海洋大学	金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162117A (en) *	1991-11-22	1992-11-10	Schering Corporation	Controlled release flutamide composition
JP2575590B2 (ja) *	1992-07-31	1997-01-29	塩野義製薬株式会社	トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
CA2140929C (fr) *	1992-08-25	2006-09-12	Michael L. Vazquez	Hydroxyethylaminosulfonamides utiles comme inhibiteurs de la protease retrovirale
US7115632B1 (en) *	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
IL144215A0 (en) *	1999-01-13	2002-05-23	Warner Lambert Co	1-heterocycle substituted diarylamines
GB0003224D0 (en) *	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
IL161036A0 (en) *	2001-09-24	2004-08-31		Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
WO2004006909A1 (fr) *	2002-07-17	2004-01-22	Titan Pharmaceuticals, Inc.	Combinaison de medicaments chimiotherapeutiques visant a augmenter l'activite antitumorale
RU2005105693A (ru) *	2002-07-30	2005-07-10	Центарис ГмбХ (DE)	Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний
AU2006235487B2 (en) *	2005-04-12	2011-12-22	Elan Pharma International Limited	Nanoparticulate quinazoline derivative formulations
WO2006115154A1 (fr) *	2005-04-22	2006-11-02	Kissei Pharmaceutical Co., Ltd.	Polymorphisme cristallin d'hydrochlorure d'acide 4’-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3’,5’-dimethylbiphenylcarboxylique
MX2008002114A (es) *	2005-07-21	2008-04-17	Ardea Biosciences Inc	Inhibidores de n-(arilamino)-sulfonamida de mek.
JP2007099763A (ja) *	2005-09-08	2007-04-19	Toyama Chem Co Ltd	ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) *	2005-12-21	2008-01-01	Organon Nv	Compounds with medicinal effects due to interaction with the glucocorticoid receptor

2008
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/fr not_active Ceased
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/ja active Pending
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/pt not_active Application Discontinuation
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/zh not_active Expired - Fee Related
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
- 2008-07-28 AP AP2010005134A patent/AP2817A/xx active
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 CA CA2693390A patent/CA2693390C/fr not_active Expired - Fee Related
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/ko not_active Ceased
- 2008-07-28 EA EA201400552A patent/EA032294B1/ru not_active IP Right Cessation
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/fr not_active Ceased
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/zh not_active Expired - Fee Related
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/es active IP Right Grant
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/ko not_active Ceased
- 2008-07-28 EA EA201000268A patent/EA020624B1/ru not_active IP Right Cessation
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/ko not_active Ceased
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/es unknown
- 2010-01-29 CR CR11244A patent/CR11244A/es not_active Application Discontinuation
- 2010-01-29 CO CO10009526A patent/CO6470808A2/es not_active Application Discontinuation
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/es unknown
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/es unknown
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/fr unknown
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/es unknown
- 2010-02-19 MA MA32636A patent/MA31881B1/fr unknown
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/ja not_active Expired - Fee Related
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/ja active Pending

Also Published As

Publication number	Publication date
CN101808516B (zh)	2013-08-28
EA201000268A1 (ru)	2010-08-30
CA2693390A1 (fr)	2009-02-05
AP2817A (en)	2013-12-31
KR20150091434A (ko)	2015-08-10
DOP2010000045A (es)	2010-10-31
HN2010000203A (es)	2012-11-19
MA31881B1 (fr)	2010-12-01
NZ582929A (en)	2012-03-30
CR11244A (es)	2010-05-20
EA020624B1 (ru)	2014-12-30
PH12015501914A1 (en)	2017-07-31
IL203296A (en)	2017-06-29
AU2008282338B2 (en)	2015-02-12
KR20140098185A (ko)	2014-08-07
EA201400552A1 (ru)	2014-09-30
JP2017125021A (ja)	2017-07-20
EP2184984A4 (fr)	2013-07-24
CA2693390C (fr)	2017-01-17
JP2010535232A (ja)	2010-11-18
HK1147396A1 (en)	2011-08-12
CN101808516A (zh)	2010-08-18
AP2010005134A0 (en)	2010-02-28
KR20100092424A (ko)	2010-08-20
CO6470808A2 (es)	2012-06-29
WO2009018233A1 (fr)	2009-02-05
EP2184984A1 (fr)	2010-05-19
AU2008282338A1 (en)	2009-02-05
CN103479604A (zh)	2014-01-01
ECSP109910A (es)	2010-04-30
CN103479604B (zh)	2016-08-10
MX2010001244A (es)	2010-08-31
EA032294B1 (ru)	2019-05-31
SV2010003469A (es)	2010-04-30
BRPI0815659A2 (pt)	2014-09-30
AU2015200390B2 (en)	2017-02-23
JP2015078199A (ja)	2015-04-23
JP6309880B2 (ja)	2018-04-11

Publication	Publication Date	Title
TN2010000049A1 (en)	2011-09-26	Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
UA99731C2 (ru)	2012-09-25	Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
CY1122808T1 (el)	2021-05-05	Ενωσεις ετεροαρυλιου χρησιμες ως αναστολεις toy ενζυμου ενεργοποιησης της sumo
HUS1600021I1 (hu)	2016-06-28	MEK inhibitorok és módszerek azok felhasználására
EP4321513A3 (fr)	2024-05-08	Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
MX2009012168A (es)	2009-12-09	Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MY139399A (en)	2009-09-30	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
TW200734311A (en)	2007-09-16	New compounds
EP3483143A8 (fr)	2020-04-15	Dérivés de pipéridinone comme inhibiteurs de mdm2 pour le traitement du cancer
WO2012048129A3 (fr)	2012-07-26	Inhibiteurs de kinase de type polo
IN2012DN03085A (fr)	2015-07-31
WO2010053583A3 (fr)	2010-09-16	Mimétiques cd4 à petite molécule et leurs utilisations
MY149512A (en)	2013-09-13	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200613243A (en)	2006-05-01	Novel compounds
MY169274A (en)	2019-03-21	Fused, tricyclic sulfonamide inhibitors of gamma secretase
SA520411406B1 (ar)	2022-08-28	مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1
WO2010129918A8 (fr)	2011-01-20	Promédicaments à base de triptolide
MY194116A (en)	2022-11-14	Pharmaceutical compounds
TW200420541A (en)	2004-10-16	Crystalline forms
MX378555B (es)	2025-03-10	Proceso para la preparacion de derivados del acido biliar de las sulfonilureas
NO20073725L (no)	2007-09-05	CCI-779-polymorf og dens anvendelse
MY159735A (en)	2017-01-31	Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
TW200724143A (en)	2007-07-01	Novel compounds for the treatment of inflammatory diseases
NZ735249A (en)	2018-08-31	Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease
UA105167C2 (uk)	2014-04-25	Кальцієва сіль периндоприлу або її сольват